Catalog Advanced Search
-
Contains 1 Component(s)
Hosted by AASLD's Portal Hypertension SIG. This webinar will explore the new field of endohepatology.
Originally presented on September 13, 2023.
Attendees will learn about the endoscopic techniques that are now being applied to the diagnosis and management of patients with liver disease.
Moderator: Don Rockey, MD
Speakers:
Reem Sharaiha, MD | Zachary Henry, MD | Theo Heller, MD
-
Contains 1 Component(s)
This will be a single lecture reviewing the differential diagnosis of AKI, including a focus on AKI-HRS, and then review management strategies. There will be focus on terlipressin given its the publication of the recent NA RCT and its FDA approval, including indications, contraindications, and potential side effects (including the important pulmonary side effects).
This will be a single lecture reviewing the differential diagnosis of AKI, including a focus on AKI-HRS, and then review management strategies. There will be focus on terlipressin given its the publication of the recent NA RCT and its FDA approval, including indications, contraindications, and potential side effects (including the important pulmonary side effects).
Originally presented on July 20th, 2023
Presenters: Pratima Sharma, University of Michigan
Moderator: Florence Wong, University of Toronto -
Contains 1 Component(s)
During this webinar, attendees will learn about mechanistic studies and treatment options for fatigue in autoimmune liver diseases as well as mechanistic studies and treatment options for pruritus in autoimmune liver diseases.
During this webinar, attendees will learn about mechanistic studies and treatment options for fatigue in autoimmune liver diseases as well as mechanistic studies and treatment options for pruritus in autoimmune liver diseases.
Originally presented on July 11, 2023
Moderator: Michele M Tana, MD | Mitchell Mah Moud, MD
Presenters: Mark Swain, MD | Andreas Kremer, MD | Gideon Hirschfield, MDHosted by Cholestatic and Autoimmune Liver Diseases SIG
-
Contains 1 Component(s)
Sexual and gender minorities people often face discrimination and harassment due to their sexual orientation and gender identity, and this population has been identified as at risk for "health disparity" by the National Institute on Minority Health and Health Disparities. The hepatology care of transgender and gender non-binary people can be complicated, given the involvement of gender-affirming therapy, psychosocial stress, and even legal challenges. In this session, we will discuss basic knowledge about transgender patients and how to provide the best hepatology care for them.
Sexual and gender minorities people often face discrimination and harassment due to their sexual orientation and gender identity, and this population has been identified as at risk for "health disparity" by the National Institute on Minority Health and Health Disparities. The hepatology care of transgender and gender non-binary people can be complicated, given the involvement of gender-affirming therapy, psychosocial stress, and even legal challenges. In this session, we will discuss basic knowledge about transgender patients and how to provide the best hepatology care for them.
Originally presented on June 28th, 2023Presenters: Howard T. Lee, Baylor College of Medicine | Elizabeth Goacher, Duke University Medical Center | Sonali Paul, University of Chicago
Moderator: Howard T. Lee, Baylor College of Medicine | Elizabeth Goacher, Duke University Medical Center -
Contains 1 Component(s)
This webinar is part two of a two-part series which focuses on the evaluation of donors and recipients for complex LDLT cases with input from hepatology, surgery, the living donor, and the recipient. Attendees of this webinar will gain the unique perspective of the considerations at play when determining the suitability of a donor and a recipient for a complex living donor liver transplant procedure. Additionally, attendees will gain a better understand of the patient perspective of being evaluated to be a living donor, being considered as a recipient of a living donor liver transplant, and the post-donation course from a prior living liver donor and her recipient.
This webinar is part two of a two-part series which focuses on the evaluation of donors and recipients for complex LDLT cases with input from hepatology, surgery, the living donor, and the recipient. Attendees of this webinar will gain the unique perspective of the considerations at play when determining the suitability of a donor and a recipient for a complex living donor liver transplant procedure. Additionally, attendees will gain a better understand of the patient perspective of being evaluated to be a living donor, being considered as a recipient of a living donor liver transplant, and the post-donation course from a prior living liver donor and her recipient.
Originally presented on June 8th, 2023Presenters: Benjamin Samstein, MD | Deborah Bandaruk | Kimberly Schadt
Moderator: David Goldberg, MD -
Contains 1 Component(s)
This webinar is part one of a two-part series which features a hepatologist and a surgeon who helped to build and expand their center's living donor liver transplant programs. Attendees of this webinar will gain a greater understanding of how to build and sustain a high-volume living donor liver transplant program from the perspective of a hepatologist and a transplant surgeon who each helped to grow their respective living donor programs.
This webinar is part one of a two-part series which features a hepatologist and a surgeon who helped to build and expand their center's living donor liver transplant programs. Attendees of this webinar will gain a greater understanding of how to build and sustain a high-volume living donor liver transplant program from the perspective of a hepatologist and a transplant surgeon who each helped to grow their respective living donor programs.
Originally presented on May 31st, 2023.Presenters: Kiran Bambha, MD, MSc | Abhinav Humar, MD
Moderator: Pratima Sharma, MD -
Contains 1 Component(s)
Globally, alcohol-associated liver disease (ALD) accounts for 50% of liver-related deaths and is the leading indication for liver transplantation (Lee BP et al JAMA Med 2020). Abstinence from alcohol is the strongest predictor of long-term survival in ALD. While evidence-based therapies for AUD exist to increase rates of abstinence and reduce rates of heavy drinking, patients with ALD rarely receive these therapies (Rogal S et al Hepatology 2020). The barriers to accessing AUD therapy among patients with ALD are likely multifactorial. While the hepatology clinic represents a potential opportunity to provide therapy for AUD to improve clinical outcomes, this is rarely done. A recent survey (Im GY et al CGH 2020) commissioned by the AASLD ALD Special Interest Group reported that the majority (71%) hepatology providers never provide behavioral or pharmacotherapy for AUD, with the most common reason being low comfort (84%). Most (77%) reported low addiction education and 90% desired more training. We have developed this webinar proposal to address these clinical gaps by educating our hepatology community and empowering them with the tools to deliver evidence-based interventions for AUD among patients with ALD in their liver clinic. In this AASLD webinar, we provide a very clinically-applicable overview of steps that providers (hepatologists, nurse practitioners, etc.) in a liver clinic can make to address AUD for their patients with ALD. The webinar provides a multi-disciplinary approach, but focuses on what is realistic and practical for an every-day liver clinic, which can have variable resources and patient populations.
Hosted by: ALD SIG
Our target audience may be broad with a mix of healthcare providers, researchers, possibly patients and patient advocates in all parts of the world.
-
Contains 1 Component(s)
Our understanding of “immune tolerance” in chronic hepatitis B has been evolving, with continued debates on their clinical management and treatment. This webinar will help provide updates in broad perspective, scientific context and clinical implications.
Hosted by: Hepatitis B SIG
Our target audience may be broad with a mix of healthcare providers, researchers, possibly patients and patient advocates in all parts of the world. Our understanding of “immune tolerance” in chronic hepatitis B has been evolving, with continued debates on their clinical management and treatment. So, this webinar will help provide updates in broad perspective, scientific context and clinical implications. In this context, our stated learning objectives and expected outcomes are:
Learning Objectives:
Learners will be able to understand the underlying concept and controversies around the definition of immune tolerance, to inform their clinical care and education.
Learners will be able to apply these concepts to clinical monitoring, therapeutic decisions and patient education.
Expected program outcome:
Promote further open dialogue among international hepatology community regarding mechanisms and significance of apparent immune tolerance in HBV-infected patients
Increased scientific activities and knowledge with collaborations and funding on this topic
-
Contains 2 Component(s)
Webinar hosted by the Women's Initiatives Committee on Tuesday, December 13, 2022.
The purpose of this webinar is to discuss the issues facing women who wish to pursue an academic career in Hepatology. The idea behind is that examining the obstacles and the difficulties will help in identifying the possible solutions.
The webinar will start with the trailer of the very relevant documentary “Picture a Scientist” as an introduction to formal presentations, which will examine the problem of academic disadvantage, both in terms of poor recognition of career progression and authorship. Two lectures will be an exemplification of real careers by a junior and a senior faculty member, and lastly a lecture will be devoted to identify possible resources.
There will then be a 20-minute discussion between panelists and a Q and A session to involve the audience, directed by our moderator.
Erica Villa (Moderator)
Professor of Gastroenterology
University of Modena and Reggio Emilia
Tatyana Kushner (Moderator)
Associate Professor, Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
Tatyana Kushner, MD, MSCE, is Assistant Professor in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York. She completed her medical school and internal medicine training at Mount Sinai School of Medicine, a fellowship in gastroenterology and a masters in clinical epidemiology at the University of Pennsylvania, and a fellowship in transplant hepatology at the University of California, San Francisco (UCSF). Her research focuses on both epidemiologic and patient-centered outcomes in viral hepatitis, with an emerging focus in the area of women’s health and pregnancy care, and the goal of developing and studying interventions to improve clinical outcomes in this patient population. She has recently established a Women's Liver Clinic at Mount Sinai in order to enhance the diagnosis and management of liver disease during pregnancy and post-delivery, particularly of hepatitis B and hepatitis C.
Monika Sarkar (Moderator)
Marina Berenguer
Guadalupe Garcia-Tsao
Guadalupe Garcia-Tsao, MD, FAASLD is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.
Kathleen E. Corey
Kathleen E. Corey, MD, MPH, MMSc is the Director of the MGH Non-Alcoholic Fatty Liver Disease (NAFLD) Clinic, Associate Program Director for the Medicine Residency for Clinical and Translational Research, a hepatologist who specializes in NAFLD, Physician Investigator in the CTEU, and an Assistant Professor of Medicine at HMS.
Dr. Corey’s interests include clinical and translational research in NAFLD. She aims to better understand predictors of development and progression of NAFLD, the interplay between cardiovascular disease and NAFLD and the natural history of NAFLD in persons living with HIV (PLWH). She is the Co-PI for an R01 evaluating the role of tesamorelin, a growth hormone-releasing hormone for the treatment of NAFLD and is involved in an NIH-funded study on the prevalence, risk factors and treatment of NAFLD in PLWH.
Dr. Corey earned her MD at Duke University School of Medicine, her MPH from the University of North Carolina and her MMSc from Harvard Medical School. Prior to joining the faculty of MGH, she completed her training in Internal Medicine, Chief Residency, Gastroenterology and Advanced Hepatology and Liver Transplant at MGH.
Rotonya Carr, MD
Anita Chong, PhD
-
Contains 2 Component(s)
Webinar hosted by the Hypertension SIG on Monday, December 12, 2022.
There is emerging data showing benefits of diagnosing clinically significant portal hypertension and its treatment to prevent decompensation. The field is rapidly evolving, specifically with respect to non-invasive modalities of measurement. This webinar will review currently available non-invasive tests to measure clinically significant portal hypertension including blood tests, liver stiffness and spleen stiffness. Use of non-invasive measurements in special populations such as those with fatty liver disease and those who have achieved sustained virological response as well as how to monitor improvements in clinically significant portal hypertension without ongoing injury are also areas of interest which will be addressed.
There will then be a 20-minute discussion between panelists and a Q and A session to involve the audience, directed by our moderator.
Maja Thiele, MD, PhD
Dr. Maja Thiele works to reduce morbidity and mortality from alcohol-related liver disease, for the benefit of an otherwise stigmatized patient group. Her research centers on the development and validation of diagnostic and prognostic biomarkers, with a particular focus on early disease detection, cost-effective referral pathways and omics technologies. Elastography expert contributor to EASL Clinical Practice Guidance, the BAVENO VII consensus statement, and AASLD clinical guidance. Partner in the European research consortia GALAXY, LiverScreen, MicrobPredict and SALVE.
Annalisa Berzigotti
Annalisa Berzigotti graduated in Medicine in Bologna, Italy, where she also obtained the title of specialist in Internal Medicine and a Doctorate in ultrasound in medicine. She expanded her knowledge in hepatology at the Hepatic hemodynamic Laboratory of the Liver Unit of the Hospital Clinic, University of Barcelona, Spain, where she obtained a Doctorate in hepatology. In December 2014 she joined the hepatology group of the Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Switzerland. Since March 2021 she is chief of the liver group and ad interim clinic director at the Department of Visceral Surgery and Medicine, Bern University Hospital. Annalisa Berzigotti has been member of the Governing Board of the European Association for the Study of the Liver in 2016-2019. Since 2022 she is Liver Representative at the United European Gastroenterology (UEG) Council. She is Associate Editor of the Journal of Hepatology and of Seminars in Liver Disease. Her main research interests include portal hypertension and non-invasive assessment of liver disease.
Atoosa Rabiee, MD
Annalisa Berzigotti graduated in Medicine in Bologna, Italy, where she also obtained the title of specialist in Internal Medicine and a Doctorate in ultrasound in medicine. She expanded her knowledge in hepatology at the Hepatic hemodynamic Laboratory of the Liver Unit of the Hospital Clinic, University of Barcelona, Spain, where she obtained a Doctorate in hepatology. In December 2014 she joined the hepatology group of the Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Switzerland. Since March 2021 she is chief of the liver group and ad interim clinic director at the Department of Visceral Surgery and Medicine, Bern University Hospital. Annalisa Berzigotti has been member of the Governing Board of the European Association for the Study of the Liver in 2016-2019. Since 2022 she is Liver Representative at the United European Gastroenterology (UEG) Council. She is Associate Editor of the Journal of Hepatology and of Seminars in Liver Disease. Her main research interests include portal hypertension and non-invasive assessment of liver disease.
